1
Orphan Designations
0 approved
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Verlyx Pharma, Inc. is a company with 1 orphan drug designation across 4 rare diseases. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| intrahepatic bile duct cancer | pentamidine | Des.TrialAppr. |
| liver angiosarcoma | pentamidine | Des.TrialAppr. |
| liver cancer | pentamidine | Des.TrialAppr. |
| liver failure | pentamidine | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
5
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
1
affecting portfolio